Senseonics (NYSE:SENS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $2.00 target price on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

SENS opened at $0.41 on Friday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11. The company has a market cap of $216.02 million, a PE ratio of -2.91 and a beta of 0.79. The stock has a 50-day moving average of $0.41 and a 200-day moving average of $0.46. Senseonics has a 52-week low of $0.32 and a 52-week high of $0.75.

Senseonics (NYSE:SENS) last announced its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. As a group, equities research analysts forecast that Senseonics will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Several large investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC raised its holdings in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Senseonics in the first quarter valued at $162,000. Price T Rowe Associates Inc. MD lifted its position in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the period. Vanguard Group Inc. boosted its stake in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Senseonics during the first quarter worth $91,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.